Clinical trials: Healthy Control Subjects
Hypersensitivity
Sugammadex Hypersensitivity Study (Study P06042)
This trial was conducted to study the potential for hypersensitivity symptoms at the time of initial exposure to sugammadex and upon repeat exposure, since it was unknown whether the frequency or severity of hypersensitivity…
- Trial name
- NCT00988065
- Testing
- Sugammadex 4 mg/kg, Sugammadex 16 mg/kg
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03315936
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Epilepsy
fMRI Guided TMS Enhancement of Associative Memory Networks
This is a randomized, single-blinded, controlled phase 1 study to demonstrate feasibility and explore the neurophysiologic and clinical effects of repetitive transcranial magnetic stimulation (TMS) interventions in epilepsy…
- Trial name
- NCT02749422
- Testing
- MagStim RapidStim2
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy
A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)
The purpose of this study is to assess safety, tolerability and pharmacokinetics of D5884 following administration of single and multiple doses in healthy male Japanese subjects.
- Trial name
- NCT02209766
- Testing
- D5884
- Where
- Japan
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability of TAK-418 following single oral doses in healthy participants.
- Trial name
- NCT03228433
- Testing
- TAK-418
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Takeda
Pain
Reduction in Pain Intensity Following IV or Oral Pain-relieving Products
The purpose of this study is to evaluate two experimental pain models to see if they would be useful for comparing different products for reduction in pain intensity.
- Trial name
- NCT02678416
- Testing
- IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Morphine (Treatment D)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Influenza
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
The present study aims to evaluate safety, tolerability and immunogenicity of three lots of Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine…
- Trial name
- NCT00310804
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
- Where
- 2 sites in Lithuania
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy, Botulinum Toxin
Single or Repeat Dose of G03-52-01 in Adult Subjects
A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
- Trial name
- NCT05348993
- Testing
- G03-52-01
- Where
- 15 sites in United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteers
MLN3126 Single Rising Dose Study
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of MLN3126 when administered as a single dose of tablets at escalating dose levels in healthy participants.
- Trial name
- NCT02447458
- Testing
- MLN3126
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Takeda
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Tuberculosis
First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects
GSK3036656 is being developed by GSK for the treatment of tuberculosis (TB). This is the FTIH study for GSK3036656 to evaluate the safety, tolerability and PK of single ascending and repeat oral doses of GSK3036656 in healthy…
- Trial name
- NCT03075410
- Testing
- GSK3036656
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
TAK-935 Multiple Rising Dose Study in Healthy Participants
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple rising doses of TAK-935 in healthy participants.
- Trial name
- NCT02539134
- Testing
- TAK-935
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Takeda
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche